| Literature DB >> 35999509 |
Yunfeng Bai1, Xiao-Ming Zhang1, Xiangyu Sun1, Jiaming Li1, Jing Cao1, Xinjuan Wu2.
Abstract
BACKGROUND: Some studies associate frailty and postoperative mortality in hip or knee replacement patients, and others have explored the relationship between the frailty index and changes in postoperative mortality in hip or knee replacement patients, but their findings are not consistent. This meta-analysis and systematic review aimed to pool the results of existing studies to explore whether frailty is an independent risk factor for postoperative mortality in patients with lower limb arthroplasty (including hip or knee arthroplasty).Entities:
Keywords: Frailty; Meta-analysis; Mortality; Total hip arthroplasty; Total knee arthroplasty
Mesh:
Year: 2022 PMID: 35999509 PMCID: PMC9400276 DOI: 10.1186/s12877-022-03369-w
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 4.070
Summary of Included Studies on frailty associated with mortality among lower limb arthroplasty patients
| Author | Design | County | Male% | Setting | Prevalence of frailty | Sample size | Age/years | Frailty Criteria | Effect measures | Outcome assessed |
|---|---|---|---|---|---|---|---|---|---|---|
| Laursen 2021 [ | RCS | Denmark | 56% | Hospital | 20% | 284 | 74(67–80) | modified Frailty index | RR | 90-day mortality |
| Johnson 2021 [ | RCS | USA | 43.5% | Hospital | 23% | 5341 | Aged> 50 years | Frailty index | HR | 1-year mortality |
| Ferguson 2021 [ | PCS | UK | 38.8% | Hospital | 37.4% | 6682 | Aged> 65 years | electronic Frailty index | RR | 90-day mortality |
| Schwartz 2021 [ | RCS | USA | 38% | Hospital | 19.8% | 179,702 | 66.4 ± 6.6 | modified Frailty index | RR | 30-day mortality |
| R.L Johnson 2018 [ | PCS | USA | 48.8% | Hospital | 22.7% | 8640 | Aged> 50 years | Frailty index | HR | 90-day mortality |
| Mclsaac D. I 2016 [ | RCS | Canada | 39% | Hospital | 2.4% | 125,163 | 74(6) | ACG | HR | 1-year mortality |
| Mclsaac 2016 [ | RCS | Canada | 44.4% | Hospital | 3.1% | 134,782 | Aged> 65 years | ACG | HR | 1-year mortality |
| R.L Johnson 2021 [ | PCS | USA | 45.8% | Hospital | NA | 18,397 | 68(61,75) | Frailty index | HR | In-hospital mortality |
| Runner 2017 [ | RCS | USA | 37.2% | Hospital | NA | 90,260 | 70.75 ± 7.17 | modified Frailty index | OR | In-hospital mortality |
| Shin 2016 [ | RCS | USA | 40.5% | Hospital | NA | 39,807 | Aged> 18 years | modified Frailty index | OR | In-hospital mortality |
| Sophia 2018 [ | RCS | USA | 55.2% | Hospital | NA | 140,158 | 64.8 | modified Frailty index | OR | In-hospital mortality |
| Traven 2019 [ | RCS | USA | 41.1% | Hospital | NA | 16,304 | 65.2 | modified Frailty index | OR | In-hospital mortality |
RCS Retrospective cohort study, PCS prospective cohort study, ACG Johns Hopkins Adjusted Clinical Groups frailty-defining diagnoses indicator, HR hazard ratio, OR odd ratio, RR risk ratio
Fig. 1Research screening flowchart
Fig. 2Meta-analysis of the effects of frailty on mortality among lower limb arthroplasty patients
Fig. 3Meta-analysis of the effects of frailty on mortality based on different population
Fig. 4Meta-analysis of the effects of frailty on mortality based on different assessment tools
Fig. 5Meta-analysis of the effects of frailty on mortality based on different study design
Fig. 6Meta-analysis of the effects of frailty on mortality based on different geographic region
Fig. 7Meta-analysis of the effects of frailty on mortality based on follow-up
Results of quality assessment using the Newcastle-Ottawa scale quality for cohort studies
| Newcastle-Ottawa scale | Selection (1) | Comparability (2) | Outcome (3) | Total (9) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Was follow-up long enough for outcome to occur? | Adequacy of follow-up of cohorts | ||
| Laursen 2021 [ | ☆ | ☆ | ☆ | ☆ | ☆☆ | ☆ | – | ☆ | 8 |
| Johnson 2021 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |
| Ferguson 2021 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |
| Schwartz 2021 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |
| R.L Johnson 2018 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |
| Mclsaac D. I 2016 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |
| Mclsaac 2016 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |
| R.L Johnson 2021 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |
| Runner 2017 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |
| Shin 2016 [ | ☆ | ☆ | ☆ | ☆ | ☆☆ | ☆ | – | ☆ | 8 |
| Sophia 2018 [ | ☆ | ☆ | ☆ | ☆ | ☆☆ | ☆ | – | ☆ | 8 |
| Traven 2019 [ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | – | ☆ | 7 |